Table 1 Demographic, clinical and laboratory characteristics of 411 patients with primary myelofibrosis stratified by absolute basophil count (ABC) and absolute eosinophil count (AEC).

Number (%)

411

362 (88)

49 (12)

396 (96)

15 (4)

359 (87)

52 (13)

Age (years, median)

64

63

67

0.01

64

66

0.2

64

65

0.2

Range

22–87

22–84

46–87

22–87

49–72

22–87

35–81

Female, n (%)

145 (35)

132 (36)

13 (27)

0.2

142 (36)

3 (20)

0.2

129 (36)

16 (31)

0.5

Male, n (%)

266 (65)

230 (64)

36 (73)

254 (64)

12 (80)

230 (64)

36 (69)

Palpable splenomegaly, n (%)

301 (75)

263 (74)

38 (79)

0.4

291 (75)

10 (71)

0.8

265 (75)

36 (72)

0.6

Hemoglobin, g/dL; median

11.3

11.2

11.5

0.9

11.3

10.7

0.6

11.2

11.6

0.06

Range (evaluable n = 332)

7.9–16.1

7.9–16.1

8.2–14.9

7.9–16.1

8.2–12.8

7.9–16.0

8.2–16.1

While blood cell, x10⁹/L; median

9.6

8.4

31

< 0.01

9.1

61

< 0.01

8.3

30.3

< 0.01

Range(evaluable n = 404)

1.0–218.5

1.0–120.6

3.9–218.5

1.0–120.6

7.9–218.5

1.0–112.4

4.8–218.5

Absolute Basophil count,

0.13

0.1

1.5

0.1

3.4

0.1

0.7

X10⁹/L, median (Range)

(0–23.9)

0–0.8

(0.84–23.9)

(0–1.8)

(2–23.9)

(0–2.9)

(0–23.9)

Absolute Eosinophil count,

0.12

0.1

0.6

0.1

2.9

0.09

1.3

x10⁹/L, median (Range)

(0–19.6)

(0–2.7)

(0–19.6)

(0–3.4)

(0–19.6)

(0–0.6)

(0.6–19.6)

Platelets, x10⁹/L; median

212

213

207

0.4

213

165

0.2

206

277

0.06

Range

11–2466

11–2282

14–2466

11–2466

14–885

11–2466

14–885

Peripheral blasts, %; median

1

1

2

< 0.01

1

1

0.2

1

1

0.02

Range

0–15

0–15

0–13

0–15

0–13

0–15

0–13

Peripheral blasts ≥ 2%, n (%)

131 (32)

104 (29)

27 (55)

124 (31)

7 (47)

107 (30)

24 (46)

Lactate dehydrogenase U/L, median

516

511

669

0.03

516

1148

0.02

515

565

0.4

Range (evaluable n = 225)

136–1961

136–1901

230–1961

136–1901

294–1961

136–1433

138–1961

 Low, n (%)

47 (11)

47 (13)

0 (0)

47 (12)

0 (0)

41 (11)

6 (11.5)

 Intermediate-1, n (%)

69 (17)

68 (19)

1 (2)

< 0.01

68 (17)

1 (7)

0.02

63 (18)

6 (11.5)

0.3

 Intermediate-2, n (%)

162 (39)

140 (39)

22 (45)

158 (40)

4 (27)

144 (40)

18 (35)

 High, n (%)

133 (32)

107 (29)

26 (53)

123 (31)

10 (67)

111 (31)

22 (42)

 Low, n (%)

31 (9)

30 (10)

1 (3)

31 (9)

0 (0)

20 (10)

1 (2)

 Intermediate, n (%)

132 (38)

122 (40)

10 (25)

0.04

130 (39)

2 (13)

0.03

119 (39)

13 (31)

0.06

 High, n (%)

138 (40)

116 (38)

22 (55)

128 (39)

10 (67)

114 (38)

24 (57)

 Very high risk, n (%)

44 (13)

37 (12)

7 (17)

41 (12)

3 (20)

40 (13)

4 (10)

MIPPS70+ V 2.0 (evaluable n = 341)

< 0.01

< 0.01

0.1

 Low, n (%)

71 (21)

69 (23)

2 (5)

71 (22)

0 (0)

65 (22)

6 (14)

 Intermediate-1, n %)

63 (19)

61 (20

2 (5)

63 (19)

0(0)

59 (20)

4 (10)

 Intermediate-2, n (%)

158 (46)

132 (44)

26 (65)

147 (45)

11 (73)

135 (45)

23 (55)

 High, n (%)

49 (14)

39 (13)

10 (25)

45 (14)

4 (27)

40 (13)

9 (21)

JAK2 V617F mutated, n (%)

249 (60.0)

215 (59)

34 (69)

0.2

239 (60)

10 (67)

0.6

209 (58)

40 (77)

< 0.01

MPL mutated, n (%)

29 (7)

28 (8)

1 (2)

0.09

28 (7)

1 (7)

1.0

27 (7)

2 (4)

0.3

CALR mutated, n (%)

90 (23)

74 (23)

6 (12)

0.06

89 (22)

1 (7)

0.1

87(23)

3 (5)

< 0.01

Type 1/like CALR mutated, n (%)

73 (18)

69 (19)

4 (8)

0.04

72 (18)

1 (7)

0.2

71 (20)

2 (4)

< 0.01

 median

52

60

26

< 0.01

58

24

< 0.01

59

34

< 0.01

 Range

0–453

0–453

2–197

0–453

2-53

0–453

2–284

Allogeneic stem cell transplants; n (%)

28 (7)

26 (7)

2 (4)

0.4

27 (7)

1 (7)

1.0

25 (7)

3 (6)

0.7

Leukemic transformations; n (%)

45 (11)

40 (11)

5 (10)

0.9

42 (11)

3 (20)

0.3

40 (11)

5 (10)

0.7

Deaths; n (%)

335 (82)

287 (79)

48 (98)

< 0.01

320 (81)

15 (100)

0.01

288 (80)

47 (90)

0.06